Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: Report from a high level conference

Journal of Viral Hepatitis

Volumn 23, Issue , 2016, Pages 1-12

  Papatheodoridis, G ^a   Thomas, H C ^b   Golna, C ^c   Bernardi, M ^d   Carballo, M ^e   Cornberg, M ^f   Dalekos, G ^g   Degertekin, B ^h   Dourakis, S ^a   Flisiak, R ⁱ   Goldberg, D ^j   Gore, C ^c,k   Goulis, I ^l   Hadziyannis, S ^a   Kalamitsis, G ^m   Kanavos, P ⁿ   Kautz, A ^o   Koskinas, I ^a   Leite, B R ^p   Malliori, M ^a   Manolakopoulos, S ^a   Maticic M ^q   Papaevangelou, V ^a   Pirona, A ^r   Prati, D ^s   Raptopoulou Gigi, M ^t   Reic, T ^o   Robaeys, G ^u   Schatz, E ^v   Souliotis, K ^w   Tountas, Y ^a   Wiktor, S ^e   Wilson, D ^x   Yfantopoulos, J ^a   Hatzakis, A ^a   more..

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c Hepatitis B and C Public Policy Association   (Luxembourg)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g UNIVERSITY OF THESSALY   (Greece)

^h ACIBADEM UNIVERSITY   (Turkey)

ⁱ MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^j HEALTH PROTECTION SCOTLAND   (United Kingdom)

^k Hepatitis C Trust   (United Kingdom)

^l ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^m Hellenic Liver Patient Association Prometheus   (Greece)

ⁿ LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^o European Liver Patients' Association ELPA   (Belgium)

^p National Parliament   (Portugal)

^q UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^r European Monitoring Center for Drugs and Drug Addiction   (Portugal)

^s A MANZONI HOSPITAL   (Italy)

^t Hellenic Centre for Disease Control and Prevention (HCDCP)   (Greece)

^u DEPARTMENT OF CARDIOLOGY   (Belgium)

^v Correlation Network ^*  (Netherlands)

^w UNIVERSITY OF PELOPONNESE   (Greece)

^x WORLD BANK   (United States)

more..

Author keywords

barriers to prevention; care; fiscal constraints; treatment; viral hepatitis

Indexed keywords

HEPATITIS B VACCINE; HEPATITIS C VACCINE; TENOFOVIR;

ARTICLE; COST EFFECTIVENESS ANALYSIS; EUROPE; EVIDENCE BASED MEDICINE; HEALTH CARE ACCESS; HEALTH PROMOTION; HEPATITIS B; HEPATITIS C; HUMAN; PATIENT CARE; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PUBLIC HEALTH; SECONDARY PREVENTION; SOCIAL DISCRIMINATION; SOCIAL STIGMA; WORLD HEALTH ORGANIZATION; EVIDENCE BASED PRACTICE; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC;

EUROPE; EVIDENCE-BASED PRACTICE; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HEPATITIS B; HEPATITIS B, CHRONIC; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; SOCIAL DISCRIMINATION; SOCIAL STIGMA;

EID: 84957108719     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12493     Document Type: Article

References (63)

1. European Centre for Disease Prevention and Control (ECDC). Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies, 2010. Available at: http://ecdc.europa.eu/en/publications/Publications/TER-100914-Hep-B-C%20-EU-neighbourhood.pdf (accessed 10 December 2013).
2. Hanafiah K, Groeger J, Flaxman A, Wiersma S,. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. J Hepatol 2013; 57 (4): 1333-1342.
3. Ni Y, Chang M, Wu J, Hsu H, Chen H, Chen D,. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol 2012; 57: 730-735.
4. Lee W,. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745.
5. World Health Organization (WHO). Regional office for Europe. Hepatitis B, Fact Sheet No 204, 2014. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/ (accessed 5 December 2014).
6. Lindenbach B, Rice C,. Unravelling hepatitis C virus replication from genome to function. Nature 2005; 436 (7053): 933-938.
7. World Health Organisation (WHO). Guidelines for the screening, care and treatment of persons with hepatitis C infection, 2014. Available at: http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/ (accessed 10 December 2014).
8. Cornberg M, Razavi H, Alberti A, et al,. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011; 31 (2): 30-60.
9. World Health Organization (WHO). Hepatitis Data and Statistics, 2013. Available at: http://www.euro.who.int/en/health-topics/communicable-diseases/hepatitis/data-and-statistics (accessed 10 November 2014).
10. World Health Organization (WHO). Immunization, Vaccines and Biologicals, Hepatitis, 2013. Available at: http://www.who.int/immunization/topics/hepatitis/en/ (accessed 6 October 2014).
11. Quelhas R, Lopes A,. Psychiatric problems in patients infected with hepatitis C before and during antiviral treatment with interferon-alpha: a review. J Psychiatr Pract 2009; 15 (1): 262-281.
12. Tavakkoli M, Ferrando S, Rabkin J, Marks K, Talal A,. Depression and fatigue in chronic hepatitis C patients with and without HIV co-infection. Psychosomatics 2013; 54 (5): 466-471.
13. Fábregas B, de Ávila R, Faria M, Moura A, Carmo R, Teixeira A,. Health related quality of life among patients with chronic hepatitis C: a cross-sectional study of sociodemographic, psychopathological and psychiatric determinants. Braz J Infect Dis 2013; 17 (6): 633-639.
14. Razavi H, Elkhoury A, Elbasha E, et al,. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013; 57 (6): 2164-2170.
15. Vietri J, Prajapati G, El Khoury A,. The burden of hepatitis C in Europe from the patients' perspective: a survey in 5 countries. BMC Gatroenterol 2013; 13 (16): 1-8.
16. Backx M, Lewszuk A, White J, et al,. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy. J Viral Hepatitis 2014; 21: 208-215.
17. Wolffram I, Petroff D, Bätz O, et al,. Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios. J Hepatol 2015; 62: 1256-1264.
18. Chang T, Lai C, Kew Yoon S, et al,. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 52: 422-430.
19. Marcellin P, Gane E, Buti M,. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-475.
20. Papatheodoridis G, Buti M, Cornberg M, et al,. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57 (1): 167-185.
21. World Health Organization (WHO). Hepatitis C, Fact Sheet No 164, 2014. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/ (accessed 2 May 2015).
22. Viktor S,. Global control of viral hepatitis: Are the pieces falling into place? June 3-4. Athens High Level Meeting:, Hepatitis B and C Public Policy Association; 2014. Report No.: Athens.
23. van der Meer A, Veldt B, Feld J, et al,. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308 (24): 2584-2593.
24. World Health Organization (WHO). Prevention and control of viral hepatitis infection: framework for global action, 2012. Available at: http://www.who.int/csr/disease/hepatitis/Framework/en/ (accessed 2 August 2014).
25. World Health Organization (WHO). World Health Assembly 67, Agenda Item 12.3, Hepatitis WHA67.6, 2014. Available at: http://apps.who.int/gb/ebwha/pdf-files/WHA67/A67-R6-en.pdf (accessed 5 September 2014).
26. Papatheodoridis G, Tsochatzis E, Hardtke S, Wedemeyer H,. Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review. Liver Int 2014; 34 (10): 1452-1463.
27. European Centre for Disease Prevention and Control (ECDC). Hepatitis B and C surveillance in Europe 2012, 2014. Available at: http://www.ecdc.europa.eu/en/publications/Publications/hepatitis-b-c-surveillance-europe-2012-july-2014.pdf (accessed 10 November 2014).
28. Wiktor SJ,. Where next for hepatitis B and C surveillance? J Viral Hepatitis 2015; 22 (7): 571-573.
29. Chen D,. Hepatitis B vaccination: the key towards elimination and eradication of hepatitis B. J Hepatol 2009; 50: 805-816.
30. Romanò L, Paladini S, Tagliacarne C, Zappa A, Zanetti A,. The changing face of the epidemiology of type A, B, and D viral hepatitis in Italy, following the implementation of vaccination. Vaccine 2009; 27 (25-26): 3439-3442.
31. Campagna M, Siddu A, Meloni A, Murru C, Masia G, Coppola R,. Epidemiological Impact of Mandatory Vaccination against Hepatitis B in Italian Young Adults. Hepat Mon 2011; 11 (9): 750-752.
32. Fitzsimons D, Kojouharova M, Hallauer J, Hendrickx G, Vorsters A, Van Damme P,. Burden and prevention of viral hepatitis in Bulgaria. Vaccine 2009; 29 (47): 8471-8476.
33. World Health Organization (WHO). Vaccine-preventable diseases, Hepatitis B, 2013. Available at: http://www.euro.who.int/en/health-topics/disease-prevention/vaccines-and-immunization/vaccine-preventable-diseases/hepatitis-b (accessed 5 October 2014).
34. Van Damme P, Leuridan E, Hendrickx G, et al,. Should Europe have a universal hepatitis B vaccination programme? BMJ 2013; 347: 4057.
35. Turner K, Hutchinson S, Vickerman P, et al,. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 2011; 106 (11): 1978-1988.
36. Bruggmann P,. Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers. J Viral Hepatitis 2012; 19 (12): 829-835.
37. Bruggman P, Grebely J,. Prevention, treatment and care of hepatitis C among people who inject drugs. Vienna, 2014. Available at: https://www.unodc.org/documents/hiv-aids/CND2014/UNODC-SCIENTIFIC-EVENT-HCV-BRUGGMANN.pdf (accessed 5 November 2014)
38. Matser A, Urbanus A, Geskus R,. The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam. Addiction 2012; 107 (3): 614-623.
39. Iversen J, Grebely J, Topp L, Wand H, Dore G, Maher L,. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011. J Viral Hepat 2014; 21 (3): 198-207.
40. Aspinall E, Corson S, Doyle J, et al,. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 2013; 57 (2): 80-89.
41. Robayes G, Grebely J, Mauss S, et al,. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis 2013; 57 (2): 129-137.
42. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Prisons and drugs in Europe: the problem and responses, 2012. Available at: http://www.emcdda.europa.eu/publications/selected-issues/prison (accessed 2 September 2014).
43. World Health Organization (WHO). Global Database on Blood Safety, Summary Report 2011, 2011. Available at: http://www.who.int/bloodsafety/global-database/GDBS-Summary-Report-2011.pdf (accessed 9 October 2014).
44. Perkins H, Busch M,. Transfusion-associated infections: 50 years of relentless challenges and remarkable progress-associated infections: 50 years of relentless challenges and remarkable progress. Transfusion 2010; 50 (10): 2080-2099.
45. Allain J, Mihaljevic I, Gonzalez-Fraile M, et al,. Infectivity of blood products from donors with occult hepatitis B virus infection. Transfusion 2013; 53 (7): 1405-1415.
46. Borkent-Raven B, Janssen M, Van der Poel C, Bonsel G, Van Hout B,. Cost-effectiveness of additional blood screening tests in the Netherlands. Transfusion 2012; 52 (3): 478-488.
47. Centers for Disease Prevention and Control (CDC). Health care settings and viral hepatitis, 2011. Available at: http://www.cdc.gov/hepatitis/settings/HealthcareSettings.htm (accessed 6 October 2014).
48. World Health Organization (WHO). Injection safety policy and global campaign, 2015. Available at: http://www.who.int/injection-safety/global-campaign/en/ (accessed 1 May 2015).
49. Treloar C, Rance J, Dore G, Grebely J,. Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study. J Viral Hepatitis 2014; 21: 560-567.
50. McGowan C, Bacon B, Mallolas J, et al,. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. J Hepatol 2013; 57 (4): 1325-1332.
51. Shehab T, Sonnad S, Lok A,. Management of hepatitis C patients by primary care physicians in the USA: results of a national survey. J Viral Hepatitis 2001; 8 (5): 377-383.
52. Papatheodoridis G, Hatzakis A,. Public health issues of hepatitis C virus infection. Best Pract Res Clin Gastroenterol 2012; 26 (4): 371-380.
53. Maticic M, Videcnik Zorman J, Gregorcic S, Schatz E, Lazarus J,. Are there national strategies; plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries BMC Infect Dis 2014; 14 (6): 14.
54. Carballo M, Cody R, Kelly M, Hatzakis A,. Migration, Hepatitis B, and Hepatitis C, 2013. Available at: http://www.hepbcppa.org/wp-content/uploads/2011/11/Migration-report.pdf (accessed 3 October 2014).
55. Jones L, Atkinson A, Porcellato L, et al,. A systematic review of qualitative research on the views, perspectives and experiences of hepatitis B and C testing among practitioners and people at greatest risk of infection, Final Report for the National Institute for Clinical Excellence, 2011. Available at: https://www.nice.org.uk/guidance/ph43/resources/hepatitis-b-and-c-ways-to-promote-and-offer-testing-evidence-review-12 (accessed 6 October 2014).
56. Treloar C, Rance J, Backmund M,. Understanding barriers to hepatitis C virus care and stigmatization from a social perspective. Clin Infect Dis 2013; 57 (2): 51-55.
57. Yehia B, Schranz A, Umscheid C,. Lo Re V. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS ONE 2014; 9 (7): 1-7.
58. World Health Organization (WHO). Guidelines for the screening, care and treatment of persons with hepatitis C infection, 2014. Available at: http://apps.who.int/iris/bitstream/10665/111747/1/9789241548755-eng.pdf (accessed 1 May 2015).
59. Razavi H,. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepatitis 2014; 1 (1): 34-59.
60. Robaeys G, Nevens F, Starkel P, et al,. Previous intravenous substance use and outcome of liver transplantation in patients with chronic hepatitis C infection. Transpl Proc 2009; 41 (2): 589-594.
61. World Health Organization (WHO). Health, health systems and economic crisis in Europe. Impact and policy implications. Summary, European Observatory on Health Systems and Policies, 2013. Available at: http://www.euro.who.int/--data/assets/pdf-file/0011/186932/Health-and-economic-crisis-in-Europe4.pdf (accessed 4 September 2014).
62. RAND. Hepatitis C-A projection of the healthcare and economic burden in the UK, 2013. Available at: http://www.rand.org/content/dam/rand/pubs/technical-reports/TR1300/TR1307/RAND-TR1307.pdf (accessed 10 April 2015).
63. Wedemeyer H, Duberg A, Buti M, et al,. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 2014; 21 (1): 60-89.